Biogen (NASDAQ/BGEN) today announced several key appointments to its senior management.
Robert A. Hamm has been appointed Vice President, Sales and Marketing, replacing Michael W. Bonney, who has announced his intention to resign at the end of this year.
As a senior executive with Biogen since 1994, Mr. Hamm has played a critical role in building Biogen’s international commercial structure and operating capability. As Director of Northern Europe, he helped lead the creation of Biogen’s European commercial organization and founded many international distributor relationships outside of Northern Europe. More recently, as Vice President, Manufacturing, Mr. Hamm led the development of Biogen’s global supply chain strategy, including the creation of its North Carolina large-scale manufacturing operations, a world-class operation for protein molecule production.
Sylvie L. Gregoire, Pharm.D., has been appointed Vice President, Manufacturing. Dr. Gregoire was most recently Vice President, Regulatory Affairs. She joined Biogen in 1995 as Director, Regulatory Affairs-Europe.
Nadine Cohen, Ph.D., has been appointed Vice President, Regulatory Affairs. Dr. Cohen was previously Director of Regulatory Affairs. She joined Biogen in 1999 from the Massachusetts Biologics Laboratories, where she was Senior Director of Quality Control and Technical Services. Prior to that, she was Vice President of Regulatory Affairs and Quality at Alpha Beta Technology, Inc.
James C. Mullen, Biogen’s President and Chief Executive Officer, said “Mike Bonney has made many important contributions to Biogen during his tenure with the company. As Vice President of Sales, he established our U.S. sales department and led it to its position of pre-eminence in the MS marketplace. As Vice President of Sales and Marketing, he continued to build on the strengths and successes of this group of dedicated professionals. We appreciate his many contributions and will miss him.
“I am pleased that Bob Hamm is moving into the key leadership position in Sales and Marketing. Bob is a dedicated and versatile executive who has played a key role in several critical areas of our organization, including establishing and managing a significant portion of our European sales and marketing organization. His new assignment, as well as those of Drs. Sylvie Gregoire and Nadine Cohen, demonstrates the depth of Biogen’s pool of senior management talent. We expect Bob, Sylvie and Nadine to play expanded roles in our company’s management during the critical months ahead.”
Biogen, Inc., winner of the U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company’s revenues are generated from U.S. and European sales of AVONEX® (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products ( Prescribing Information ). Biogen’s research and development activities are focused on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases and in developmental biology and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen’s Homepage on the World Wide Web at http://www.biogen.com.